Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list
Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic from its shortage list, a move that will sharply curtail the compounders' ability to sell cheaper versions of the drugs.
Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
Supplies of high-demand obesity treatments are improving, but that doesn’t mean it's easier to get them. Many employers and ...
The medical director of the NHS has warned of the side effects of weight loss drugs after figures revealed the number of deaths associated with the jabs ...
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
Patients on semaglutide ( Ozempic, Wegovy) had a 32% increased relative risk of developing nonarteritic anterior ischemic ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...
David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback